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Abstract
Introduction Hypoxic stress is a feature of rapidly growing thyroid tumours. Cancer progression is thought to be
driven by a small population of tumour cells possessing stem cell properties. Hypoxia-inducible factors (HIFs) are
important mediators of hypoxia. Both HIF-1alpha and HIF-2alpha have been reported to be expressed in thyroid
cancers. There is growing evidence that the HIF pathway plays a significant role in the maintenance of thyroid cancer
stem cells (CSC).
Methodology We have isolated thyroid CSC from a papillary thyroid cancer-derived cell line (BCPAP) and an
anaplastic thyroid cancer-derived cell line (SW1736) as side population (SP) cells (a putative stem cell population)
and treated them with cobalt chloride (II) to induce hypoxia.
Results and discussion We observed an increase in the SP of cells within the thyroid cancer cell lines following
induction of hypoxia.
Introduction
The worldwide incidence of thyroid cancer has been on the
increase over the past three decades [1]. The rising trend is
attributed to a better detection of subclinical cases, though
the possibility of increasing incidence due to other factors
is argued by some studies. Differentiated thyroid cancers
arising from the follicular epithelial cells of the thyroid
gland (papillary and follicular thyroid cancers) are the most
prevalent forms of thyroid cancer and have a relatively
good prognosis with over 75% survival rate at 10 years [2].
Tumour recurrence and formation of distant metastases
develop in 6–20% of cases and are the main cause of
thyroid cancer-related deaths [2–5].
In contrast, anaplastic thyroid cancer (ATC, which also
arises from the follicular epithelial cells) is an undiffer-
entiated thyroid cancer characterised by rapid growth and
high metastatic potential. ATC is often associated with pre-
existing goitre or differentiated thyroid cancer [6]. Clinical
management of ATC presents a significant challenge due to
the limited role of surgical intervention at the time of
diagnosis and limited response to other treatment modali-
ties such as radiotherapy and chemotherapy, which leads to
patients’ demise within 3–7 months of the diagnosis [6].
As disease advances, thyroid tumours may be subjected to
hypoxic stress which results in activation of hypoxia sig-
nalling pathways, involving hypoxia-inducible factors
(HIFs). HIFs are composed of an oxygen-sensitive alpha
subunit, which is degraded under normoxic conditions and
a stable beta subunit. HIF complex formed under hypoxic
conditions acts as transcriptional factor for multiple gene
targets, mainly involving cell cycle regulation (e.g. MYC,
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p53), anaerobic metabolism (Glut 1), intracellular pH
maintenance (CA9, also known as CAIX) and angiogenesis
(e.g. VEGF) allowing tumour cells to quickly adapt to the
hostile environment [7]. Growing evidence shows that
overexpression of HIF-1alpha and HIF-2alpha in thyroid
cancers is associated with more advanced tumour grade
and the presence of metastasis [8, 9]. Although HIF path-
ways appear to play a significant role in thyroid cancer
progression, the exact mechanism remains unknown.
Histologically, thyroid tumours comprise heterogeneous
populations of tumour cells, including a small population
of undifferentiated cells that exhibit stem cell properties,
such as unlimited proliferative potential, clonogenicity,
capacity for asymmetric division and advanced cell repair
mechanisms as well as the presence of efflux pumps.
Cancer stem cells (CSC) have been previously identified in
other types of solid tumours, with evidence, suggesting that
the hypoxic microenvironment promotes the undifferenti-
ated state of the CSC [10, 11]. Treatment modalities such
as radioiodine therapy, radiotherapy and chemotherapy
target metabolically active rapidly dividing mature thy-
roid cancer cells, but not CSC, which survive and can give
rise to new thyroid tumours.
Thyroid CSC have been previously isolated based on the
presence of cell surface markers, including CD133 and
CD44, their potential to generate thyrospheres, the pres-
ence of putative stem cells markers such as Oct4, Sox2 and
Nanog, fluorescent-activated cell sorting (FACS) based on
ALDH activity and as side population (SP) cells. However,
the use of surface markers to identify thyroid CSC has been
controversial as many studies demonstrated that these are
not uniquely or consistently expressed by thyroid CSC.
The SP assay has been used to successfully isolate
thyroid stem cell-enriched SP from thyroid tissue and
thyroid cell lines [12–15]. The SP analysis is based on the
cell’s ability to efflux vital dyes most commonly Hoechst
33342 dye, with this efflux property being mediated by
ABC-transporters, and this can be reversed using ABC-
transporter inhibitors such as verapamil.
In this study, we assess the effect of hypoxia on the SP
fraction in thyroid cell lines representing normal follicular
thyroid cells, papillary thyroid cancer and anaplastic thy-
roid cancer.
Methodology
Cell lines
Nthy ori 3-1 representing human follicular thyroid cells
were obtained from the European Collection of Cell Cul-
tures (ECACC). BCPAP (PTC-derived) and SW1736
(ATC-derived) cell lines were kindly provided by Professor
G. Brabant (Lubeck, Germany) and Professor McCabe
(Birmingham, UK). BCPAP and SW1736 harbour a BRAF
V600 E mutation which is present in estimated 45% PCT
and 20% of ATC [16, 17]. All cell lines were verified using
STR fingerprinting. Nthy ori 3-1 and BCPAP cells were
cultured in RPMI 1640 culture medium, and SW1736 was
cultured in high-glucose DMEM medium supplemented
with 2 mM L-glutamine (Sigma), 10% foetal bovine serum
(Life technologies) and 100 Iu/ml penicillin and strepto-
mycin (Gibco).
Cobalt chloride (II) hexahydrate (CoCl2) treatment
Cobalt chloride (a hypoxia-mimetic) was used to induce
hypoxia in thyroid cell lines. The cells were treated with
100 lM for 48 h. Untreated cells were used as controls.
Activation of HIF pathway was confirmed by PCR on the
treated cells. Results were compared to thyroid cells incu-
bated at 0.5% O2 for 48 h in a Ruskinn hypoxia chamber.
Semi-quantitative PCR
RNA extraction was performed using RNAeasy Plus Micro
Kit (Qiagen) as per manufacturer’s instructions. RNA
concentration was measured, and RNA integrity was
checked using gel electrophoresis on a 2% agarose gel.
cDNA was made with Tetro cDNA synthesis kit (Bioline)
using equal amount of RNA for all samples and as per
manufacturer’s instructions. PCR was performed using
12.5 ll PCR mastermix (Promega), 0.5 lg/ll primers (Life
technologies), 2.5 ll cDNA template and nuclease free
water, to make up a final reaction volume of 25 ll. Primer
sequences used are provided in Table 1. PCR cycle pro-
gramme was as follows: denaturation 30 s at 94 C,
annealing temperature optimised for each primer for 30 s,
elongation 1 min at 72 C, 35 cycles. The amplified
products were run on a 2% agarose gel and visualised
under UV light using a GelDoc-It imager (UVP). Band
intensity was measured using image J programme. GAPDH
was used for standardisation.
Side population assay
Cells were incubated in low-serum media (2%FBS) and
Hoechst 33342 dye using a pre-optimised SP protocol for
each thyroid cell line. 100 lM of verapamil (Sigma) was
added to block ABC-transporters efflux ability. Post-incu-
bation, the cells were washed with ice-cold PBS, filtered
and analysed on LSR Fortessa flow cytometer (BD Bio-
sciences). Cell debris and non-viable cells were identified
using propidium iodide and excluded from the analysis as
well as doublet cells. Data were analysed using BD
FACSDiva software (version 8).
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Results
Expression of hypoxia markers
Standard PCR was performed to confirm HIF pathway
activation by measuring mRNA expression of HIF-1alpha,
HIF-2alpha and their downstream gene targets CA9 and
VEGF in the thyroid cell lines treated with 100 lM of
COCl2 for 48 h (Fig. 1).
HIF-1alpha mRNA was strongly expressed in all three
untreated samples. Following hypoxia induction, the levels
Table 1 Sequence of primers used in standard PCR
Gene Primer sequence Product length (base pairs)
Oct3/4 Forward: AGTGAGAGGCAACCTGGAGA
Reverse: ACACTCGGACCACATCCTTC
110
Sox2 Forward: AACCCCAAGATGCACAACTC
Reverse: GCTTAGCCTCGTCGATGAAC
100
Nanog Forward: TTCCTTCCTCCATGGATCTG
Reverse: TCTGCTGGAGGCTGAGGTAT
213
HIF-1alpha Forward: TCATCCAAGAAGCCCTAACG
Reverse: TCGCTTTCTCTGAGCATTCTG
112
HIF-2alpha Forward: TCTGAAAACGAGTCCGAAGCC
Reverse: GGTCGCAGGGATGAGTGAAGT
196
CA9 Forward: ATCGCTGAGGAAGGCTCAGA
Reverse: AGGGTGTCAGAGAGGGTGTG
195
VEGF Forward: TGTGTGTGTGTGAGTGGTTGA
Reverse: TCTCTGTGCCTCGGGAAG
69
GAPDH Forward: GCACCGTCAAGGCTGAGAAC
Reverse: GCCTTCTCCATGGTGGTGAA
150
Fig. 1 Graphs showing relative mRNA expression of the hypoxia markers in the untreated sample and after 48 h of treatment with cobalt
chloride in Nthy ori 3-1 (a), BCPAP (b) and SW1736 (c). n = 1
World J Surg
123
remained relatively similar in all three treated samples
compared to the controls.
HIF-2alpha mRNA was expressed in the untreated
BCPAP and SW1736, but not in Nthy ori 3-1. Following
CoCl2 treatment, the mRNA expression sharply rose in
Nthy ori 3-1, but a downward trend in expression was
observed in BCPAP and SW1736.
The mRNA levels of HIF-1alpha and HIF-2alpha, CA9
and VEGF increased in Nthy ori-3-1 and SW1736 fol-
lowing induction of hypoxia, but remained unchanged in
the treated BCPAP.
The effect of hypoxia on SP population
SP analysis was performed on the three cell lines cells
treated with 100 lM of CoCl2 for 48 h. Untreated cells
were used as control (Fig. 2).
The untreated Nthy ori 3-1 (A) BCPAP (C) and SW1736
(E) all contained a small SP cell population. However,
following hypoxia induction with CoCl2, the Nthy ori 3-1
SP fraction was reduced (B), while there was a significant
increment in SP fractions in both the BCPAP (D) and
SW1736 (F) cells. A graphical representation of data from
three independent experiments of the SP analysis following
hypoxia induction showing the mean percentage change in
SP for each cell line (2b) confirms the impact of hypoxia
treatment, with mean SP reduction of 68% for Nthy ori 3-1,
and mean SP increase of 400% for BCPAP and 120% for
SW1736, however, changes for all 3 where not significant
using a two-sided t test.
The effect of hypoxia on stem cell marker expression
Transcription factors Oct4, Sox2 and Nanog regulate
expression of genes involved in maintaining pluripotency
and regulation of self-renewal. Using standard PCR,
mRNA expression was examined in untreated and CoCl2-
treated cells (Fig. 3).
Following hypoxia treatment, the levels of Oct4 and
Nanog mRNA increased in Nthy ori 3-1 and Sox2 mRNA
levels became detectable in the treated sample. In BCPAP,
hypoxia resulted in upregulation of Sox2 and Oct4 with
slight reduction in Nanog mRNA levels. No Sox2 expres-
sion was detected in the treated or untreated SW1736, but
stronger expression of Oct4 and Nanog was seen following
hypoxic treatment.
Discussion
The CSC model for thyroid carcinogenesis, which is based
on the principle that a small subset of the cells within
tumour bulk has the capacity to generate and propagate
tumours, has become more widely acceptable in the recent
years due to identification of thyroid cancer cell popula-
tions possessing a stem cell phenotype. Longer life span
and aberrant cell cycling regulation mean that CSC are
more likely to accumulate genetic mutations necessary to
transform into cancerous cells unlike normal tissue cells
[10]. Thyroid CSC origin remains debatable with specu-
lations that CSC may be transformed stem cells residing in
the thyroid tissue or that they may have arisen as a result of
dedifferentiation of the mature thyroid cancer cells.
In our experiments, we used cobalt chloride to induce a
hypoxic state in thyroid CSC. Cobalt chloride acts by
reducing intracellular ascorbate levels which promotes iron
oxidation. Iron acts as a substrate for the enzyme propyl
hydroxylase, which is responsible for hydroxylation of
HIF-alpha subunits. This stops binding of von Hippel–
Lindau protein and E3 uniquitin ligase to HIF-alpha and
results in its subsequent degradation [18]. This method of
inducing hypoxia has been used in a number of studies
[9, 19].
The SP assay is a validated technique that was used to
isolate CSC-enriched population from different types of
solid organ tumours including breast, gastric, intestine,
prostate and thyroid [12, 20]. We previously determined
that sorted SP from SW1736 and BCPAP exhibits stem cell
characteristics such as their ability to generate both SP and
non-SP (asymmetric division) and had higher expression of
the stemness markers and lacked expression of thyroid
differentiation markers (data not shown). All three thyroid
cell lines used in the study were found to contain an SP.
Although the SP fraction was consistently lower in the
normal thyroid cell line Nthy ori 3-1(around 0.1–0.5%), SP
value in the two thyroid cancer cell lines was found not to
be related to the thyroid tumour type.
Previously, both HIF-1alpha and HIF-2alpha were found
to be expressed at protein level in thyroid cancer tissues,
but not in the normal tissues and their overexpression was
found to be correlated with tumour aggressiveness and
metastases [21, 22].
cFig. 2 a FACS plots showing SP in Nthy ori 3-1 before (A) and after
treatment with 100 lM of cobalt chloride (B), in BCPAP before
(C) and after treatment with 100 lM of cobalt chloride (D), and in
SW1736 before (E) and after treatment with 100 lM of cobalt
chloride (F). In each case, SP phenotype was confirmed by addition of
verapamil. Note decrease in SP in Nthy ori 3-1 and increase in SP in
BCPAP and SW1736 following induction of hypoxia. b Graphical
representation of flow cytometry data from three independent
experiments of the SP analysis following cobalt chloride-induced
hypoxia. Results are expressed as mean percentage change in SP, and
bars represent SEM (p = 0.09 Nthy ori 3-1, p = 0.344 BCPAP,
p = 0.404 SW1736)
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In our study, we observed differences in HIFs mRNA
expression in the treated cell lines, suggesting that the
hypoxia may differently regulate HIF-1alpha and HIF-
2alpha expression in normal and cancerous thyroid cell
lines, thus leading to activation of different cellular path-
ways. HIF-1alpha was found to be expressed in all three
thyroid cell lines during normoxia, and the levels remain
relatively stable after 48 h of hypoxic treatment which may
be reflective of the fact that post-transcriptional and post-
translational regulation of HIF-1alpha occurs, and mea-
surement of protein levels rather than mRNA levels would
be more accurate.
HIF-2alpha was upregulated in the normal thyroid cell
line following hypoxia treatment. When Nthy ori 3-1 was
treated with CoCl2 for 2, 24, 48 and 72 h, HIF-1alpha
levels increased on induction of hypoxia and then declined
over time and the opposite pattern was seen with HIF-
2alpha expression (data not shown), suggesting that HIF-
1alpha may mediate acute phase response to hypoxia and
HIF-2alpha target genes may be recruited in the chronic
hypoxic response. HIF-2alpha can mediate stem cell phe-
notypes by directly inducting Oct4 transcription, and in our
experiments we observed increased stem cell markers
expression following CoCl2 treatment, but a fall in the SP
fraction in the treated Nthy ori 3-1 after 48 h, possibly due
to the normal thyroid cells being more sensitive to the
effects of hypoxic treatment with more cells succumbing to
hypoxia than proliferating.
The presence of BRAF mutation in BCPAP and
SW1736 can aberrantly activate HIF pathway independent
Fig. 3 a PCR products of stem
cells markers gene expression in
untreated Nthy ori 3-1, BCPAP
and SW1736 and following
treatment with cobalt chloride.
GAPDH was used as
housekeeping gene. b Graphs
showing change in the
expression of mRNA of putative
stem cell markers following
hypoxic treatment. The values
shown are relative to
housekeeping gene GAPDH
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of hypoxia, promoting overactive MEK/EPK signalling
which results in increased HIF protein synthesis, suggest-
ing that activation of the HIF pathway is essential in thy-
roid cancer progression [8]. This is supported by our
finding that HIF-2alpha mRNA was detected only in the
cancerous thyroid cell lines in the normoxic state and the
levels remained relatively unchanged following hypoxia
induction. In SW1736, both HIF-1alpha and HIF-2alpha
mRNA expression decreased with CoCl2 treatment; how-
ever, the target genes CA9 and VEGF were upregulated,
confirming that the pathway had been activated. In the
BCPAP cell line, we did observe mRNA for CA9 remained
unchanged even after hypoxia treatment. This may be a
limitation of the analysis method used as changes may have
been too small to detect or it may be that mRNA levels
were unaltered, but changes in protein expression might
still occur. Burrows and colleagues did demonstrate an
increase in CA9 in the BCPAP cell line following induc-
tion of hypoxia using cobalt chloride (II) at the protein
level [9].
In both thyroid cancer cell lines, hypoxia resulted in an
increase in the SP fraction and upregulation of stem cell
markers mRNA; however, further experiments would be
required to confirm statistical significance of these findings.
Both HIF-1alpha and HIF-2alpha can induce CSC popu-
lations, but appear to do so by activating different stem cell
pathways. HIF-1alpha is responsible for stabilising Notch
1, another important pathway in promoting undifferentiated
state of the cells, as well as promoting invasive and
metastatic characteristics of the tumour by activating
transcription factors regulating epithelial-to-mesenchymal
transition (EMT), one of the main processes by which
metastases are thought to occur. Furthermore, cells
undergoing EMT can generate tumour cells with cancer
stem cell characteristics [23].
Although it had been previously described that hypoxia
markers were related to the higher degree of thyroid
tumour dedifferentiation and invasiveness, this is the first
study that looked at the association between hypoxia, HIFs
and thyroid cancer stem cells.
It’s becoming increasingly evident that eradication of
solid organ tumours would require elimination of the
cancer stem cell population, in which the current treatment
modalities such as chemotherapy, radiotherapy and
radioactive iodine ablation (RAI) fail to target. Targeting
HIF activity could ultimately lead to reduction in thyroid
CSC numbers, thus impairing regeneration and metastatic
potential of thyroid tumours and making them more sus-
ceptible to the effects of RAI, radiotherapy and
chemotherapy. There are a number of agents in clinical
trials that target HIF’s activity as well as inhibiting the
members of the HIF signalling pathways (Table 2). Fur-
thermore, CSC markers have been shown to be reliable
predictors of tumour recurrence in other types of solid
tumours and their role in disease surveillance in thyroid
cancers should be further explored [24].
Table 2 Summary of most recent clinical trials targeting HIFs and their downstream target genes
Drug name Mechanism of action Neoplasm Clinical trial
phase
Clinical trial identification
number
EZN-2968 HIF-1alpha mRNA antagonist Liver, lymphoma 1 NCT 0176393
PT2385 HIF-2alpha inhibitor Glioblastoma 1 NCT03216499
Digoxin HIF-1alpha inhibitor Breast cancer 1 NCT0176393
R07070179 HIF-alpha mRNA antagonist Liver 1 NCT02564614
PX-478 HIF-1alpha inhibitor lymphoma 1 NCT00522652
PT2977 HIF-2alpha inhibitor Kidney 1 NCT02293980
BAY87-2243 HIF-1alpha protein suppression Various advanced solid organ
tumours
1 NCT01297530
Bevacizumab Anti-VEGF monoclonal
antibody
Breast 3 NCT00109239
Pancreas 1 NCT00447710
Rectal 2 NCT00113230
Sevacizumab Anti-VEGF monoclonal
antibody
Colorectal 1 NCT02453464
Lucitanib VEGFR/FGFR inhibitor Lung 2 NTC02109016
Aflibercept VEGF inhibitor Ovarian 1 NCT00327171
Breast 2 NCT00436501
colorectal 2 Multiple
DTP348 CA9 inhibitor Head and neck 1 NTC02216669
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Conclusion
Hypoxia may be contributing to progression of thyroid
cancer by promoting generation of treatment-resistant stem
cell-enriched SP. Two HIF isoforms, HIF-1alpha and HIF-
2alpha, may play different roles in thyroid carcinogenesis.
Further understanding of the cellular pathways involved is
essential in the development of future treatments that could
target thyroid CSC.
Acknowledgements This work was funded in part by grants from the
British Association of Endocrine and Thyroid Surgeons and the Get
Ahead charitable trust and supported by the flow cytometry facility at
Newcastle University.
Funding This work was funded in part by grants from the British
Association of Endocrine and Thyroid Surgeons (Grant Number
BH154364) and the Get Ahead charitable trust (Grant Number
BH164226).
Compliance with Ethical Standards
Conflict of interest The authors have nothing to disclose.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Kitahara C, Sosa J (2016) The changing incidence of thyroid
cancer. Nat Rev Endocrinol 12:646–653
2. Madani A, Tabah R, How J et al (2015) Rare metastases of well-
differentiated thyroid cancers: a systematic review. Ann Surg
Oncol 22:460–466
3. Benbassat C, Hirsch D (2006) Clinicopathological characteristics
and long-term outcome in patients with distant metastases from
differentiated thyroid cancer. World J Surg 30:1088–1095
4. Durante C, Baudin E, Leboulleux S et al (2006) Long-term
outcome of 444 patients with distant metastases from papillary
and follicular thyroid carcinoma: benefits and limits of radio-
iodine therapy. J Clin Endocrinol Metab 91:2892–2899
5. Lee J (2010) Differentiated thyroid carcinoma presenting with
distant metastasis at initial diagnosis clinical outcomes and
prognostic factors. Ann Surg 251:114–119
6. Chiacchio S, Lorenzoni A, Boni G et al (2008) Anaplastic thyroid
cancer: prevalence, diagnosis and treatment. Minerva Endocrinol
33:341–357
7. Majmundar AJ, Wong WJ, Simon MC (2010) Hypoxia-inducible
factors and the response to hypoxic stress. Mol Cell 40:294–309
8. Burrows N, Babur M, Resch J et al (2011) Hypoxia-inducible
factor in thyroid carcinoma. J Thyroid Res 2011:762905
9. Burrows N, Resch J, Cowen RL et al (2010) Expression of
hypoxia-inducible factor 1 alpha in thyroid carcinomas. Endocr
Relat Cancer 17:61–72
10. Moore N, Lyle S (2011) Quiescent, slow-cycling stem cell pop-
ulations in cancer: a review of evidence and discussion of sig-
nificance. J Oncol. https://doi.org/10.1155/2011/396076
11. Seidel S, Garvalov BK, Wirta V et al (2010) A hypoxic niche
regulates glioblastoma stem cells through hypoxia inducible
factor 2a. Brain 133:983–995
12. Mitsutake N, Iwao A, Nagai K et al (2007) Characterization of
side population in thyroid cancer cell lines: cancer stem-like cells
are enriched partly but not exclusively. Endocrinology
148:1797–1803
13. Lan L, Cui D, Nowka K et al (2007) Stem cells derived from
goiters in adults form spheres in response to intense growth
stimulation and require thyrotropin for differentiation into thy-
rocytes. J Clin Endocrinol Metab 92:3681–3688
14. Chen G, Xu S, Renko K et al (2012) Metformin inhibits growth of
thyroid carcinoma cells, suppresses self-renewal of derived can-
cer stem cells and potentiates the effect of chemotherapeutic
agents. J Clin Endocrinol Metab 97:E510–E520
15. Zheng X, Cui D, Xu S et al (2010) Doxorubicin fails to eradicate
cancer stem cells derived from anaplastic thyroid carcinoma
cells: characterisation of resistant cells. Int J Oncol 37:307–315
16. Xing M (2005) BRAF mutation in thyroid cancer. Endocr Relat
Cancer 12:245–262
17. Guerra A, Di Crescenzo V, Garzi A et al (2013) Genetic muta-
tions in the treatment of anaplastic thyroid cancer: a systematic
review. BMC Surg 13:S44
18. Salnikow K, Donald SP, Bruick RK et al (2004) Depletion of
intracellular ascorbate by the carcinogenic metals nickel and
cobalt results in the induction of hypoxic stress. J Biol Chem
279:40337–40344
19. Cho J, Kim D, Lee S et al (2005) Cobalt chloride-induced
estrogen receptor a down-regulation involves hypoxia-inducible
factor-1a in MCF-7 human breast cancer cells. Mol Endocrinol
19:1191–1199
20. Patrawala L, Schneider-Broussard R, Zhou J et al (2005) Side
population is enriched in tumorigenic, stem-like cancer cells,
whereas ABCG2? and ABCG2- cancer cells are similarly
tumorigenic. Can Res 65:6207–6219
21. Koperek O, Akin E, Asari R et al (2013) Expression of hypoxia
inducible factor 1 alpha in papillary thyroid carcinoma is asso-
ciated with desmoplastic stromal reaction and lymph node
metastases. Virchows Arch 463:795–802
22. Wang N, Dong CR, Jiang R (2014) Overexpression of HIF-1al-
pha, metallothionein and SLUG is associated with high TNM
stage, lymph node metastases in papillary thyroid carcinoma. Int
J Clin Exp Patholog 7:322–330
23. Lan L, Cui D (2013) Epithelial-mesenchymal transition triggers
cancer stem cell generation in human thyroid cancer cells. Int J
Oncol 43:113–120
24. de Jong MC, Pramana J, van der Wal JE et al (2010) CD44
expression predicts local recurrence after radiotherapy in larynx
cancer. Clin Cancer Res 16:5329–5338
World J Surg
123
